Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Xenetic Biosciences Inc (NQ: XBIO ) 4.520 -0.010 (-0.23%) Streaming Delayed Price Updated: 3:51 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 17,335 Open 4.230 Bid (Size) 4.490 (3) Ask (Size) 4.740 (2) Prev. Close 4.530 Today's Range 4.130 - 4.730 52wk Range 2.780 - 5.200 Shares Outstanding 1,542,139 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Monday's Intraday Session September 30, 2024 Via Benzinga Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference September 11, 2024 Via ACCESSWIRE Performance YTD +26.78% +26.78% 1 Month +10.53% +10.53% 3 Month +12.71% +12.71% 6 Month -2.38% -2.38% 1 Year +10.23% +10.23% More News Read More Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update August 14, 2024 Via ACCESSWIRE XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024 August 13, 2024 Via InvestorPlace Xenetic Biosciences, Inc. Announces Executive Leadership Transition May 22, 2024 Via ACCESSWIRE Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update May 10, 2024 Via ACCESSWIRE Xenetic Biosciences: Q3 Earnings Insights November 10, 2023 Via Benzinga Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference October 11, 2023 Via ACCESSWIRE Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results August 11, 2023 Via ACCESSWIRE XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023 March 22, 2024 Via InvestorPlace Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results March 22, 2024 Via ACCESSWIRE Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform January 17, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Tuesday's Intraday Session December 05, 2023 Via Benzinga Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results November 10, 2023 Via ACCESSWIRE Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series July 05, 2023 Via ACCESSWIRE Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences May 16, 2023 Via Benzinga Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023 Via ACCESSWIRE Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 Via ACCESSWIRE 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 20, 2023 Via Benzinga Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session May 15, 2023 Via Benzinga Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison May 03, 2023 Via ACCESSWIRE 12 Health Care Stocks Moving In Friday's Intraday Session May 12, 2023 Via Benzinga Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock May 12, 2023 Via ACCESSWIRE Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development May 04, 2023 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
